Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LGJ2 | ISIN: FR0004163111 | Ticker-Symbol: XUP
Tradegate
31.03.25
15:22 Uhr
3,335 Euro
+0,010
+0,30 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFIT SA Chart 1 Jahr
5-Tage-Chart
GENFIT SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,2353,29021:44
3,2653,29021:45

Aktuelle News zur GENFIT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.GENFIT S.A.: GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders845GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million...
► Artikel lesen
20.03.Genfit S.A. - 6-K, Report of foreign issuer1
10.03.GENFIT S.A.: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs103All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repurchase...
► Artikel lesen
GENFIT Aktie jetzt für 0€ handeln
10.03.Genfit S.A. - 6-K, Report of foreign issuer2
27.02.GENFIT S.A.: GENFIT Announces Revenues and Cash Position as of December 31, 202482Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen's Iqirvo®...
► Artikel lesen
21.02.Genfit S.A. - 6-K, Report of foreign issuer-
21.02.Genfit reports preliminary results of repurchase offer to 2025 OCEANEs holders3
21.02.GENFIT S.A.: GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting1
14.02.GENFIT S.A.: GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders1
10.02.GENFIT S.A.: GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders5.420In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase...
► Artikel lesen
06.02.GENFIT S.A.: GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 20251372 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase...
► Artikel lesen
06.02.Genfit S.A. - 6-K, Report of foreign issuer-
30.01.GENFIT S.A.: GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan668GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additional...
► Artikel lesen
29.01.GENFIT S.A.: GENFIT Announces 2025 Financial Calendar4
29.01.Genfit S.A. - 6-K, Report of foreign issuer-
13.01.GENFIT S.A.: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial4
13.01.Genfit S.A. - 6-K, Report of foreign issuer-
13.11.24GENFIT S.A.: GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting 2024625PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare...
► Artikel lesen
08.11.24Genfit reports 9M results9
07.11.24GENFIT S.A.: GENFIT Reports Third Quarter 2024 Financial Information146Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1